PSPichet Sampatanukul

Pichet Sampatanukul

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pichet Sampatanukul has a total of 153 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Addressing the Challenges in the Identification of HER2-Low and Ultralow Breast Cancer in Asia: A Delphi Consensus

    by Milap Shah, Rowen T Yolo, Bethy S Hernowo, Trung Nguyen Cong, Gong Gyungyub, Lu Bach Kim, Manuelito A Madrid, Pathmanathan Rajadurai, Pichet Sampatanukul, Shir-Hwa Ueng, et al.

    Introduction Human epidermal growth factor receptor type 2 (HER2) is overexpressed in 15–20% of primary invasive breast cancers, serving as a key predictive and prognostic factor. HER2-low is defined as immunohistochemistry (IHC) 1+ or 2+ with in situ hybridization (ISH) negative and HER2-ultralow is defined as membrane staining that is incomplete, faint/barely perceptible, and in at most 10% of tumor cells (0+/with membrane staining). Trastuzumab deruxtecan has shown improved outcomes in multiple clinical trials between these groups. A Delphi study was conducted to address challenges in testing, sampling, and reporting, and to identify unmet needs in Asia. Methods The study comprised two online surveys and a participant meeting with 15 pathologists from nine countries in Asia and the Indo-Pacific region. Responses were recorded for 57 close-ended and 33 open-ended statements using a 1–9-point Likert scale ranging from agreement to disagreement with a consensus threshold of 75%. Results All participants completed both surveys and the meeting (100% response). Consensus was reached on 33/57 closed-ended statements (survey 1, 27/47; survey 2, 6/21), while 24/57 did not reach consensus. Ninety-three percent of participants agreed that biopsies of recurrent lesions should be performed, especially if the primary tumor was HER2-zero. Initially, participants did not reach consensus (73% agreement) on reassessing HER2 results for metastatic lesions scored as HER2-zero but later reached consensus (80% agreement). All testing-related questions reached consensus in survey 1. Conclusion This Delphi study found strong consensus on key concepts for sampling, pathological testing, interpretation, and reporting of HER2-low and ultralow breast cancer. While the opinions expressed align with current guidelines, more evidence on the clinicopathological implications is needed.


  • Aberrant promoter methylation of the PAQR3 gene is associated with prostate cancer

    by Kowit Lounglaithong, Andrey Bychkov, Pichet Sampatanukul


  • Promoter hypermethylation of SOX11 correlates with adverse clinicopathological features of human prostate cancer

    by Apiwat Pugongchai, Andrey Bychkov, Pichet Sampatanukul

    Summary: Currently available tools for early diagnosis and prognosis of prostate cancer lack sufficient accuracy. There is a need to identify novel biomarkers for this common malignancy. SOX family genes play an important role in embryogenesis and are also implicated in various cancers. SOX11 has been recently recognized as a potential tumour suppressor that is downregulated in prostate cancer. We hypothesized that hypermethylation may be responsible for SOX11 silencing in human prostate cancer. The aim of the study was to investigate SOX11 promoter methylation in prostate adenocarcinoma by comparing it with benign prostatic hyperplasia (BPH). A total of 143 human prostate tissue samples, 62 from patients with prostate cancer and 81 from patients with BPH were examined by methylation‐specific PCR. Associations between SOX11 promoter methylation and clinicopathological parameters were assessed by univariate statistics. Detection rates of SOX11 promoter methylation were 80.6% and 35.8% in prostate cancer and BPH respectively (P < 0.001). SOX11 hypermethylation was associated with adverse clinicopathological characteristics of prostate cancer, including higher PSA level (P < 0.01), Gleason score ≥ 7 (P = 0.03) and perineural invasion (P = 0.03). SOX11 methylation was positively correlated with the PSA level (P = 0.001). Our data indicated that SOX11 can be a promising methylation marker candidate for differential diagnosis and risk stratification for prostate cancer.


  • TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma

    by Andrey Bychkov, Pichet Sampatanukul, Shanop Shuangshoti, Somboon Keelawat


  • Cytohistology of hepatocellular carcinoma

    by Aileen Wee, Pichet Sampatanukul


  • Combination of EUS‐FNA and elastography (strain ratio) to exclude malignant solid pancreatic lesions: A prospective single‐blinded study

    by Pradermchai Kongkam, Narisorn Lakananurak, Patpong Navicharern, Tanyaporn Chantarojanasiri, Khin Aye, Wiriyaporn Ridtitid, Krit Kritisin, Phonthep Angsuwatcharakon, Satimai Aniwan, Rapat Pittayanon, et al.

    Background: Negative results of EUS‐FNA for solid pancreatic lesions (SPL) can be false ones. Combination with strain ratio (SR) may ensure a correct benign diagnosis of SPL.Aims: We prospectively evaluated the sensitivity rate of EUS‐FNA and EUS elastography using the strain ratio method for diagnosing SPL.Methods: Thirty‐eight patients with SPL identified by CT or MRI between January 2013 and November 2013 were included in our prospective study. EUS diagnoses were made using SR by an endosonographer who was blinded to all clinical information. In SPL with adequate cellularity, the results of EUS‐FNA were combined with strain ratio to diagnose SPL and the diagnostic value was calculated.Results: Benign SPL were diagnosed in nine patients with surgical or guided‐biopsy pathology (n = 3) and benign cells from FNA with stable disease during the 12‐month follow‐up time (n = 6). Using the best cut‐off strain ratio level at 3.17, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy rate of EUS elastography were 86.2%, 66.7%, 89.3%, 60%, and 81.6%, respectively. For the 28 patients who underwent EUS‐FNA with results of adequate cellularity; EUS‐FNA alone versus combination of results of cytology and SR provided sensitivity, specificity, PPV, NPV, and accuracy rate at 90% versus 95.2, 100% versus 71.4%, 100% versus 90.9%, 80% versus 83.3, and 92.9% versus 89.3%, respectively.Conclusions: In this prospective single‐blinded study, the negative results of both EUS‐FNA and SR were more reliable to exclude malignant SPL. The sensitivity of EUS elastography by SR was not superior to EUS‐FNA. © 2015 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd


    • 1 August 2015
      • Vol. 8  (8) , 9731-6

    Alveolar soft part sarcoma presenting as a breast metastasis in a patient with a history of thyroid cancer: a case report.

    by Andrey Bychkov, Pichet Sampatanukul

    Metastases to the breast are uncommon, accounting for 0.5% of breast tumors, and most of them are originated from lymphoma, melanoma and carcinomas of various organs. Alveolar soft part sarcoma (ASPS) is a very rare neoplasm that is usually found in the lower extremities. Lungs are the common site of dissemination and may represent initial manifestation of disease. We report a clinically unsuspected case of ASPS presenting as a breast metastasis in a 25-year-old woman. The patient's medical history was notable for a thyroid cancer treated by surgery and radioiodine ablation 2 years ago. Core needle biopsy of slowly growing breast mass yielded polygonal cells with abundant eosinophilic cytoplasm arranged into solid pattern. Differential diagnosis between apocrine cell carcinoma, paraganglioma, granular cell tumor, neuroendocrine carcinoma, ASPS and metastatic hepatocellular and renal cell carcinoma was rendered by immunohistochemistry. Strong nuclear TFE3 immunoreactivity confirmed a diagnosis of ASPS. Retrospectively a primary tumor was found in the thigh. Most likely, ASPS and thyroid cancer in the patient were growing synchronously and independently.


  • Techniques and technology in practice

    by Aileen Wee, Pichet Sampatanukul, Nirag Jhala

  • Ancillary studies

    by Aileen Wee, Pichet Sampatanukul, Nirag Jhala

  • Focal liver lesions with cystic appearance

    by Aileen Wee, Pichet Sampatanukul, Nirag Jhala